alexa A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease.


Journal of Cardiovascular Diseases & Diagnosis

Author(s): BiondiZoccai GG, Lotrionte M, Moretti C, Meliga E, Agostoni P,

Abstract Share this page

Abstract BACKGROUND: Cardiac surgery is the standard treatment for unprotected left main disease (ULM). Drug-eluting stent (DES) implantation has been recently reported in patients with ULM but with unclear results. We systematically reviewed outcomes of percutaneous DES implantation in ULM. METHODS: Several databases were searched for clinical studies reporting on > or = 20 patients and > or = 6-month follow-up. The primary end point was major adverse cardiovascular events (MACEs; ie, death, myocardial infarction, or target vessel revascularization [TVR]) at the longest follow-up. Incidence and adjusted risk estimates were pooled with generic inverse variance random-effect methods (95\% CIs). RESULTS: From 823 initial citations, 16 studies were included (1278 patients, median follow-up 10 months). Eight were uncontrolled registries, 5 nonrandomized comparisons between DES and bare-metal stents and 3 nonrandomized comparisons between DES and CABG, with no properly randomized trial. Meta-analysis for DES-based PCI showed, at the longest follow-up, rates of 16.5\% (11.7\%-21.3\%) MACE, 5.5\% (3.4\%-7.7\%) death, and 6.5\% (3.7\%-9.2\%) TVR. Comparison of DES versus bare-metal stent disclosed adjusted odds ratios for MACE of 0.34 (0.16-0.71), and DES versus CABG showed adjusted odds ratios for MACE plus stroke of 0.46 (0.24-0.90). Meta-regression showed that disease location predicted MACE (P = .001) and TVR (P = .020), whereas high-risk features predicted death (P = .027). CONCLUSIONS: Clinical studies report apparently favorable early and midterm results in selected patients with ULM. However, given their limitations in validity and the inherent risk for DES thrombosis, results from randomized trials are still needed to definitely establish the role of DES implantation instead of the reference treatment, surgery. This article was published in Am Heart J and referenced in Journal of Cardiovascular Diseases & Diagnosis

Relevant Expert PPTs

Relevant Speaker PPTs

  • Khalil Khanafer
    PPT Version | PDF Version
  • Zamaneh Kassiri
    Loss of tissue inhibitor of metalloproteinase-3 (Timp3) leads to abdominal aortic aneurysm (AAA)
    PDF Version
  • Fulvia Seccareccia
    Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: Results from an intermediate risk propensity-matched population of the Italian OBSERVANT Study
    PDF Version
  • Janardhana Rao Babburi
    An unusual case of LV Myxoma extending through Aortic Valve presented with Antero Septal Myocardial Infarction
    PDF Version

Recommended Conferences

  • 19th Annual Cardiology Congress
    August 31-September 01, 2017 Philadelphia, USA
  • 23rd International Conference on Heart Diseases & Angiology
    Oct 16-17, 2017 Budapest, Hungary
  • 20th European Cardiology Congress
    October 16-18, 2017 Budapest, Hungary
  • 3rd Global Summit on Heart Diseases
    November 02-04, 2017 Bangkok, Thailand
  • 22nd World Cardiology Congress
    December 11-12, 2017 Rome, Italy

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version